Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 15/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 14/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.42 |
| ▸ | HRH1 | P35367 | 3/20 | 0.42 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1087410 | 1.00 | CHRM3 (0.42) | CHRM3CHRM2KCNH2CYP2D6LMNA | |
| SCHEMBL1087408 | 1.00 | CHRM3 (0.42) | CHRM3CHRM2KCNH2CYP2D6LMNA | |
| SCHEMBL1088431 | 0.95 | CHRM2 (0.41) | CHRM3CHRM2KCNH2CYP2D6LMNA | |
| SCHEMBL1088427 | 0.95 | CHRM2 (0.41) | CHRM3CHRM2KCNH2CYP2D6LMNA | |
| SCHEMBL1088429 | 0.95 | CHRM2 (0.41) | CHRM3CHRM2KCNH2CYP2D6LMNA | |
| SCHEMBL1086968 | 0.90 | CHRM2 (0.44) | CHRM3CHRM2KCNH2CYP2D6LMNA | |
| SCHEMBL1087438 | 0.90 | CHRM2 (0.44) | CHRM3CHRM2KCNH2CYP2D6LMNA | |
| SCHEMBL1087435 | 0.90 | CHRM2 (0.44) | CHRM3CHRM2KCNH2CYP2D6LMNA | |
| SCHEMBL1088466 | 0.89 | ALDH1A1 (0.45) | CHRM3CHRM2KCNH2CYP2D6LMNA | |
| SCHEMBL1088465 | 0.89 | ALDH1A1 (0.45) | CHRM3CHRM2KCNH2CYP2D6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831208-B1 | QUATERNARY AMMONIUM SALTS AS M3 ANTAGONISTS | NOVARTIS AG (CH) | 2011-08-24 | — | — | EP | claimed |
| US-20090227590-A1 | QUATERNARY AMMONIUM SALTS AS M3 ANTAGONISTS | NOVARTIS AG (CH) | 2009-09-10 | — | — | US | claimed |
| EP-1831208-A1 | QUATERNARY AMMONIUM SALTS AS M3 ANTAGONISTS | Novartis AG (CH) | 2007-09-12 | — | — | EP | claimed |
| WO-2006066929-A1 | QUATERNARY AMMONIUM SALTS AS M3 ANTAGONISTS | NOVARTIS AG (CH) | 2006-06-29 | — | — | WO | claimed |
| US-8153669-B2 | Quaternary ammonium salts as M3 antagonists | NOVARTIS AG (CH) | 2012-04-10 | — | — | US | disclosed |
| EP-1831208-B1 | QUATERNARY AMMONIUM SALTS AS M3 ANTAGONISTS | NOVARTIS AG (CH) | 2011-08-24 | — | — | EP | disclosed |
| US-20090227590-A1 | QUATERNARY AMMONIUM SALTS AS M3 ANTAGONISTS | NOVARTIS AG (CH) | 2009-09-10 | — | — | US | disclosed |
| EP-1831208-A1 | QUATERNARY AMMONIUM SALTS AS M3 ANTAGONISTS | Novartis AG (CH) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006066929-A1 | QUATERNARY AMMONIUM SALTS AS M3 ANTAGONISTS | NOVARTIS AG (CH) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227590-A1 | QUATERNARY AMMONIUM SALTS AS M3 ANTAGONISTS | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885CHRM2 1/4885KCNH2 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.